ANTIFUSOGENIC ANTIVIRALS: DESIGN AND TESTING

抗融合抗病毒药物：设计和测试

• 批准号: 3506085
• 负责人: Jay F. Stearns
• 金额: $ 27.93万
• 依托单位: SERES LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-05-01 至 1992-07-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3506085
• 关键词: amantadine; antiviral agents; chemical binding; chemical structure function; computer simulation; deoxycytidine; drug design /synthesis /production; influenza; ligands; membrane fusion; microorganism hemagglutinin; plaque assay; receptor binding; virus antigen; virus envelope; virus protein; virus receptors

DESCRIPTION (adapted from applicant's abstract): This Phase-II proposal describes the synthesis of ten trial ligands to test their ability to prevent membrane fusion of influenza virus by binding to the hemagglutinin (HA) site of the envelope protein. Trial ligands that inhibit exposure of the fusion peptide of HA, and show in vitro inhibition of viral fusion, will be tested for antiviral activity by plaque assay.

描述（根据申请人的摘要改编）：该阶段提案 描述了十个试验配体的合成以测试其能力 通过与血凝素结合来预防流感病毒的膜融合 （HA）包膜蛋白的位点。 抑制暴露的试验配体 HA的融合肽，显示病毒融合的体外抑制作用， 将通过牙菌斑测定测试抗病毒活性。